Cart 0

ActiPatch® Survey Publication Confirms Significant Pain Reduction, Better Sleep & Improvement in Quality of Life

back pain osteoarthritis sciatia pain sciatica sciatica treatment sleep better

BioElectronics Corporation (the manufacturer of ActiPatch®) has recently announced that its registry study of 44,000 users of its ActiPatch 7-day trial device has been published in the prominent peer reviewed medical journal Pain Management More than 5,000 chronic pain sufferers responded to the survey and submitted an assessment.

Chronic pain is a major unmet medical need that affects 20 to 40% of the global population (more than diabetes, heart disease and cancer combined.) The majority of chronic pain causes, 80-85%, are musculoskeletal in nature. Despite using an average of 1.9 drugs for pain, 86% of the respondents reported that prior to using ActiPatch, they had pain levels of 8+ on a 11 point VAS scale- indicating severe unresolved pain. Pain was reduced an average of 57% for 65% of ActiPatch Therapy users who reported suffering from conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, sports injuries, post-surgical pain, tendonitis, and neuropathy. There were no side effects reported.

A 3-month follow-up survey indicated 80% of ActiPatch users continued to purchase and use ActiPatch. The long-term effectiveness of ActiPatch therapy was confirmed by 93% of survey respondents reporting sustained pain relief, a distinct decrease in their medication use, and a significant improvement in their quality of life.

Dr. Deepak Kotak, Executive VP of BioElectronics, a Fellow of the Royal College of Anesthesiologists said “Musculoskeletal pain is an increasing problem with few appropriate, safe, drug solutions. ActiPatch is a safe, affordable, self-treatment for chronic pain.” The details of previously completed and published clinical trials can be found at

Highlights of the 7-Day Trial Survey:

  • 71% of the consumers had an average of 54% reduction in musculoskeletal, arthritic, post-surgery, fibromyalgia and neuropathy pain.
  • 80% of the consumers said they “intended” to or would “maybe” purchase an ActiPatch after using the 7-day trial device
  • Pain relief was maintained in 93% of long term users
  • 67% of pain medication users, including opioid users, reported a moderate to complete elimination of pain medication use.
  • 70% reported better sleep
  • 74% reported they are more physically active
  • 84% reported a moderate to a great deal better quality of life.
  • There have been no adverse effects

Older Post Newer Post